Evidence map›Paper›PMID 33895864›Full record

SynthesisEuropean journal of clinical pharmacology2021

Drug-drug interactions between vitamin K antagonists and statins: a systematic review.

Anna E Engell, Andreas L O Svendsen, Bent S Lind, Tore Bjerregaard Stage, Maja Hellfritzsch, Anton Pottegård

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anna E EngellDepartment of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Kettegaard Allé 30, 2650, Hvidovre, Denmark. anna.elise.engell@regionh.dk.ORCID https://orcid.org/0000-0003-4123-0753
Andreas L O SvendsenDepartment of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.ORCID https://orcid.org/0000-0001-8050-6447
Bent S LindDepartment of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Kettegaard Allé 30, 2650, Hvidovre, Denmark.ORCID https://orcid.org/0000-0003-3866-3128
Tore Bjerregaard StageClinical Pharmacology and Pharmacy, Department of Public health, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0002-4698-4389
Maja HellfritzschClinical Pharmacology and Pharmacy, Department of Public health, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0002-9566-420X
Anton PottegårdClinical Pharmacology and Pharmacy, Department of Public health, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0001-9314-5679

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConcomitant use of vitamin K antagonists (VKA) and statins is frequent in cardiovascular patients. However, clinical guidelines on this drug combination are divergent. Therefore, we performed a systematic review to evaluate the effect of statin initiation on coagulation among VKA users.

methodsFollowing the PRISMA guidelines, we applied two broad search strategies for the drug interaction between VKA and statins in both Embase and Pubmed; 8623 unique hits were obtained. In the final sample, eight studies were included.

resultsThe most frequently used VKA in the studies was warfarin, while simvastatin was the most commonly initiated statin. All included studies showed a minor increase in the anticoagulant effect of VKA following statin initiation during VKA treatment. The reported increases in mean international normalized ratio (INR) ranged from 0.15-0.65.

conclusionThe anticoagulant effect of statin initiation in patients treated with VKA is likely to be of limited clinical relevance but should be evaluated individually.

Indexed as

AnticoagulantsBlood CoagulationDrug InteractionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInternational Normalized RatioVitamin KWarfarinAnticoagulantsHydroxymethylglutaryl-CoA Reductase InhibitorsVitamin KWarfarinAnticoagulantsDrug interactionsStatinsVitamin K antagonistsWarfarin

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.